• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NTLA

NTLA

Intellia Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD13.02

-0.11 (-0.84%)

Rating:C+

Company Profile

CEO

John Leonard

IPO Date

2016-05-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$13.09

Prev. Close

$13.13

Day Low

$12.47

Day High

$13.09

52W Low

$7.31

52W High

$28.25

Market Cap

$1.46B

Volume

3.02M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.1%

Avg Negative

9.9%

Avg Neutral

46.2%

News Feed

The Top 3 Gene Editing Stocks to Own for the Next Decade

InvestorPlace·7/12/2021·↑ positive

Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results

The Motley Fool·7/11/2021·↑ positive

Is It Too Late to Buy Intellia Therapeutics?

The Motley Fool·7/10/2021·↑ positive

A Comprehensive Guide to Genomic ETFs

Zacks Investment Research·7/9/2021·↑ positive

Looking to Play Intellia's Ground-Breaking Gene Therapy?

ETF Trends·7/6/2021·↑ positive

2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't

The Motley Fool·7/4/2021·↓ negative

Why Intellia May Have Changed Medicine Forever

The Dog of Wall Street·7/2/2021·↑ positive

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

GlobeNewsWire·7/2/2021·↑ positive

CRISPR gene-editing treatment could reach patients ‘very, very soon': Intellia CEO

CNBC·7/2/2021·↑ positive

Gene Editing Stocks Are Worth A Look After Intellia's Big Breakthrough

Forbes·7/2/2021·↑ positive